Lund — 30 March 2016 — Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2015 now is available at the company’s website: www.camurus.com For more information: Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com Rein Piir, VP Investor Relations Tel. +46 (0)70 853 72 92 ir@camurus.com About Camurus Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com
Camurus Annual Report for 2015 released
| Source: Camurus AB
Attachments
